These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16444994)

  • 21. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
    Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
    Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
    Wang J; Wang D; Zhang Q; Duan L; Tian T; Zhang X; Li J; Qiu H
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):859-71. PubMed ID: 26666755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
    Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
    Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Usefulness of FDG-PET in monitoring effects of the modality therapy for central nervous system malignant lymphoma: report of three cases].
    Masada T; Matsumoto Y; Kawai N; Tamiya T; Nagao S
    No Shinkei Geka; 2004 Aug; 32(8):859-64. PubMed ID: 15478653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs.
    Wagner T; Brechemier D; Dugert E; Le Guellec S; Julian A; Hitzel A; Beyne-Rauzy O
    Cancer Imaging; 2012 Jan; 12(1):7-12. PubMed ID: 22275725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorodeoxyglucose positron emission tomography in primary thyroid lymphoma with coexisting lymphocytic thyroiditis.
    Arabi M; Dvorak R; Smith LB; Kujawski L; Gross MD
    Thyroid; 2011 Oct; 21(10):1153-6. PubMed ID: 21875367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [
    Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
    Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.
    Yamaguchi S; Hirata K; Kaneko S; Kobayashi H; Shiga T; Kobayashi K; Onimaru R; Shirato H; Tamaki N; Terasaka S; Houkin K
    Acta Neurochir (Wien); 2015 Feb; 157(2):187-94. PubMed ID: 25488176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.
    Rozenblum L; Houillier C; Baptiste A; Soussain C; Edeline V; Naggara P; Soret M; Causse-Lemercier V; Willems L; Choquet S; Ursu R; Galanaud D; Belin L; Hoang-Xuan K; Kas A
    Neuro Oncol; 2024 Jul; 26(7):1292-1301. PubMed ID: 38366824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.
    Trägårdh M; Møller N; Sørensen M
    J Nucl Med; 2015 Sep; 56(9):1366-71. PubMed ID: 26159590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG-PET findings of the brain in lymphomatoid granulomatosis.
    Kawai N; Miyake K; Nishiyama Y; Yamamoto Y; Sasakawa Y; Haba R; Kushida Y; Tamiya T; Nagao S
    Ann Nucl Med; 2006 Dec; 20(10):683-7. PubMed ID: 17385307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
    Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
    J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
    Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
    Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of brain FDG-PET in primary CNS lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.